Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis: HELP
Articles from Rome, IT
Based on 204 articles published since 2008
||||

These are the 204 published articles about Osteoporosis that originated from Rome, IT during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9
1 Guideline Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. 2017

Tarantino, Umberto / Iolascon, Giovanni / Cianferotti, Luisella / Masi, Laura / Marcucci, Gemma / Giusti, Francesca / Marini, Francesca / Parri, Simone / Feola, Maurizio / Rao, Cecilia / Piccirilli, Eleonora / Zanetti, Emanuela Basilici / Cittadini, Noemi / Alvaro, Rosaria / Moretti, Antimo / Calafiore, Dario / Toro, Giuseppe / Gimigliano, Francesca / Resmini, Giuseppina / Brandi, Maria Luisa. ·Policlinico Tor Vergata Foundation, Orthopaedics and Traumatology, University of Rome Tor Vergata, Rome, Italy. · Department of Medical and Surgical Specialties and Dentistry, Second University of Naples, Naples, Italy. · Metabolic Bone Diseases Unit, Department of Surgery and Translational Medicine, University Hospital of Florence, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy. · Nursing Science, Center of Excellence for Culture and Nursing Research-IPASVI, University of Rome Tor Vergata, Rome, Italy. · Section of Orthopaedics and Traumatology, Centre for the Study of Osteoporosis and Metabolic Bone Disease, Treviglio-Caravaggio Hospital, Bergamo, Italy. · Metabolic Bone Diseases Unit, Department of Surgery and Translational Medicine, University Hospital of Florence, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy. marialuisa.brandi@unifi.it. ·J Orthop Traumatol · Pubmed #29058226.

ABSTRACT: BACKGROUND: The Italian Society for Orthopaedics and Traumatology conceived this guidance-which is primarily addressed to Italian orthopedic surgeons, but should also prove useful to other bone specialists and to general practitioners-in order to improve the diagnosis, prevention, and treatment of osteoporosis and its consequences. MATERIALS AND METHODS: Literature reviews by a multidisciplinary team. RESULTS: The following topics are covered: the role of instrumental, metabolic, and genetic evaluations in the diagnosis of osteoporosis; appraisal of the risk of fracture and thresholds for intervention; general strategies for the prevention and treatment of osteoporosis (primary and secondary prevention); the pharmacologic treatment of osteoporosis; the setting and implementation of fracture liaison services for tertiary prevention. Grade A, B, and C recommendations are provided based on the main levels of evidence (1-3). Toolboxes for everyday clinical practice are provided. CONCLUSIONS: The first up-to-date Italian guidelines for the primary, secondary, and tertiary prevention of osteoporosis and osteoporotic fractures are presented.

2 Editorial Oxysterols and phytosterols in human health. 2017

Massaad, Charbel / Iuliano, Luigi / Lizard, Gérard. ·Toxicology, Pharmacology and Cell Signalisation, UMR-S 1124, Université Paris Descartes, 45 rue des Saints Pères, 75270 Paris, France. Electronic address: charbel.massaad@parisdescartes.fr. · Vascular Biology & Mass Spectrometry Laboratory, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. Electronic address: luigi.iuliano@uniroma1.it. · 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' EA 7270, University Bourgogne Franche-Comté, Inserm, Dijon, France, France. Electronic address: gerard.lizard@u-bourgogne.fr. ·Chem Phys Lipids · Pubmed #28800872.

ABSTRACT: -- No abstract --

3 Editorial Trabecular Bone Score in Postmenopausal Women With Type 2 Diabetes. 2016

Cipriani, Cristiana. ·Department of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Rome, Italy. Electronic address: cristiana.cipriani@gmail.com. ·J Clin Densitom · Pubmed #27423410.

ABSTRACT: -- No abstract --

4 Editorial Romosozumab: from basic to clinical aspects. 2014

Minisola, Salvatore. ·"Sapienza" Rome University, Department of Internal Medicine and Medical Disciplines , Via del Policlinico 155, 00161 Rome , Italy +39 06 49978388 ; +39 06 49978365 ; salvatore.minisola@fastwebnet.it. ·Expert Opin Biol Ther · Pubmed #24835636.

ABSTRACT: The Wnt pathway has an important role in bone formation. Inactivation of sclerostin, an inhibitor of this pathway, has been associated with increased bone mass both in animal experiments and in human clinical trials. Romosozumab is a humanized monoclonal antibody targeting sclerostin. Preclinical studies showed that this antibody primarily increases bone formation resulting in increased bone mineral density. Initial studies carried out in humans are in line with data obtained in animals. If these results are confirmed in larger studies with fracture end-points, this monoclonal antibody with its anabolic action, will become a key drug in the treatment of osteoporosis.

5 Review Diagnosis and management of bone fragility in diabetes: an emerging challenge. 2018

Ferrari, S L / Abrahamsen, B / Napoli, N / Akesson, K / Chandran, M / Eastell, R / El-Hajj Fuleihan, G / Josse, R / Kendler, D L / Kraenzlin, M / Suzuki, A / Pierroz, D D / Schwartz, A V / Leslie, W D / Anonymous1841118. ·Division of Bone Diseases, Department of Internal Medicine Specialties, Geneva University Hospital & Faculty of Medicine, 1205, Geneva, Switzerland. serge.ferrari@unige.ch. · Department of Medicine, Holbaek Hospital, Holbaek, Denmark. · OPEN, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. · Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy. · Division of Bone and Mineral Diseases, Washington University in St Louis, St Louis, MO, USA. · Department of Clinical Sciences, Clinical and Molecular Osteoporosis Unit, Lund University, Malmö, Sweden. · Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore, Singapore. · Academic Unit of Bone Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK. · Department of Internal Medicine, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, WHO Collaborating Center for Metabolic Bone Disorders, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon. · Department of Medicine and Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada. · Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, ON, Canada. · Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, BC, Canada. · Endonet, Endocrine Clinic and Laboratory, Basel, Switzerland. · Division of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi, Japan. · International Osteoporosis Foundation, Nyon, Switzerland. · Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. · Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. ·Osteoporos Int · Pubmed #30066131.

ABSTRACT: Fragility fractures are increasingly recognized as a complication of both type 1 and type 2 diabetes, with fracture risk that increases with disease duration and poor glycemic control. Yet the identification and management of fracture risk in these patients remains challenging. This review explores the clinical characteristics of bone fragility in adults with diabetes and highlights recent studies that have evaluated bone mineral density (BMD), bone microstructure and material properties, biochemical markers, and fracture prediction algorithms (i.e., FRAX) in these patients. It further reviews the impact of diabetes drugs on bone as well as the efficacy of osteoporosis treatments in this population. We finally propose an algorithm for the identification and management of diabetic patients at increased fracture risk.

6 Review Adverse effects of media reports on the treatment of osteoporosis. 2018

Cipriani, Cristiana / Pepe, Jessica / Minisola, Salvatore / Lewiecki, E Michael. ·Department of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. cristiana.cipriani@gmail.com. · Department of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. · New Mexico Clinical Research and Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM, 87106, USA. ·J Endocrinol Invest · Pubmed #29761280.

ABSTRACT: PURPOSE: The review focused on the role that media reporting plays in the level of public awareness about osteoporosis and its influence on osteoporosis treatment decisions. METHODS: We reviewed the literature on the role of media on three main aspects influencing patient adherence to osteoporosis treatment: the awareness of osteoporosis as a major health problem, the perception of the effectiveness of osteoporosis medications, and the fear of adverse effects with osteoporosis medications. RESULTS: A review of the literature confirmed what is routinely observed in clinical practice-that media report can strongly influence the level of awareness of osteoporosis and fracture risk. Inadequate and/or incorrect information on osteoporosis in the media are associated with a low level of awareness of the disease. High-risk patients may have a poor understanding of the need for treatment. Alarming information in the media over the last 2 decades regarding effectiveness and safety of long-term osteoporosis treatment is associated with reduction in the use of osteoporosis medications. CONCLUSIONS: There is a gap between the application of clinical recommendations and patient perceptions of osteoporosis and its treatment. There is a need for better education of patients and practitioners aimed at recognizing the serious consequences of fractures and understanding the expected benefits and potential risks of treatment. Media reports that disseminate evidence-based information on the balance of benefits and risks could help to reduce the osteoporosis treatment gap and mitigate the crisis in osteoporosis care.

7 Review New anabolic therapies for osteoporosis. 2017

Minisola, Salvatore / Cipriani, Cristiana / Occhiuto, Marco / Pepe, Jessica. ·Department of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Viale del Policlinico 151, 00161, Rome, Italy. salvatore.minisola@uniroma1.it. · Department of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Viale del Policlinico 151, 00161, Rome, Italy. ·Intern Emerg Med · Pubmed #28780668.

ABSTRACT: Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of bone tissue, leading to increased bone fragility that results in fractures. Pharmacological therapy is aimed at decreasing the risk of fracture, mainly correcting the imbalance between bone resorption and formation at the level of bone remodeling units. Anabolic therapy has the capability to increase bone mass to a greater extent than traditional antiresorptive agents. The only currently available drug licensed is parathyroid hormone 1-34 (teriparatide); new drugs are on the horizon, targeting the stimulation of bone formation, and therefore improving bone mass, structure and ultimately skeletal strength. These are represented by abaloparatide (a 34-amino acid peptide which incorporates critical N-terminal residues, shared by parathyroid hormone and parathyroid hormone-related protein, followed by sequences unique to the latter protein) and romosozumab (an antibody to sclerostin). In the future, the availability of new anabolic treatment will allow a more extensive utilization of additive and sequential approach, with the goal of both prolonging the period of treatment and, more importantly, avoiding the side effects consequent to long-term use of traditional drugs.

8 Review Interventions and Therapy in Rheumatology. 2017

Muto, Mario / Giurazza, Francesco / Frauenfelder, Giulia / Marcia, Stefano / Masala, Salvatore / Guarnieri, Gianluigi. ·Neuroradiology Department, Ospedale Cardarelli, Via Antonio Cardarelli 9, Naples 80100, Italy. · Radiology Department, Università Campus Bio-Medico, Via Alvaro Del Portillo 200, Rome 00100, Italy. Electronic address: francescogiurazza@hotmail.it. · Radiology Department, Università Campus Bio-Medico, Via Alvaro Del Portillo 200, Rome 00100, Italy. · Radiology Department, Ospedale Santissima Trinità, Via Is Mirrionis 92, Cagliari 09121, Italy. · Musculoskeletal Interventional Radiology Department, Università Tor Vergata, Via di Tor Vergata, Rome 00100, Italy. ·Radiol Clin North Am · Pubmed #28774451.

ABSTRACT: Patients affected by rheumatic conditions frequently present with spine degeneration and vertebral compression fractures, mainly related to the long-term therapies with glucocorticosteroids. A mini-invasive approach provided by interventional radiology techniques, especially vertebroplasty, plays a relevant role in the pain management of these patients; vertebroplasty represents the symptomatic treatment of fracture pain, so patients must always be included in a specific therapeutic workup of the rheumatic condition. This article describes patient selection criteria, technique, and outcomes of vertebroplasty in patients affected by rheumatic disease and secondary osteoporosis caused by glucocorticosteroids.

9 Review Positioning novel biologicals in CKD-mineral and bone disorders. 2017

Tartaglione, Lida / Pasquali, Marzia / Rotondi, Silverio / Muci, Maria Luisa / Covic, Adrian / Mazzaferro, Sandro. ·Department of Cardiovascular, Respiratory, Nephrologic, Anesthetic and Geriatric Sciences, Sapienza University of Rome, Rome, Italy. · Department of Nephrology and Dialysis, University Hospital Company, Policlinico Umberto I, Rome, Italy. · Department of Nephrology, Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania. · Department of Cardiovascular, Respiratory, Nephrologic, Anesthetic and Geriatric Sciences, Sapienza University of Rome, Rome, Italy. sandro.mazzaferro@uniroma1.it. ·J Nephrol · Pubmed #28540603.

ABSTRACT: Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD), to highlight the increased burden of mortality. Aging people, frequently identified as early CKD, could suffer from either the classical age-related osteoporosis (OP) or ROD. Distinguishing between these two bone diseases may not be easy without bone biopsy. In any case, besides classical therapies for ROD, nephrologists are now challenged by the possibility of using new drugs developed for OP. Importantly, while therapies for ROD mostly aim at controlling parathyroid secretion with bone effects regarded as indirect, new drugs for OP directly modulate bone cells activity. Thus, their action could be useful in specific types of ROD. Parathyroid hormone therapy, which is anabolic in OP, could be useful in renal patients with low turnover bone disease. Denosumab, the monoclonal antibody against receptor activator of NF-κB ligand (RANK-L) that inhibits osteoclast activity and proliferation, could be beneficial in cases with high turnover bone. Use of romosozumab, the monoclonal antibody against sclerostin, which both stimulates osteoblasts and inhibits osteoclasts, could allow both anabolic and anti-resorptive effects. However, we should not forget the systemic role now attributed to CKD-MBD. In fact, therapies targeting bone cells activity could also result in unpredicted extra-bone effects and affect cardiovascular outcomes. In conclusion, the new biologicals established for OP could be useful in renal patients with either OP or ROD. In addition, their potential non-bone effects warrant investigation.

10 Review Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? 2017

Biglia, N / Cagnacci, A / Gambacciani, M / Lello, S / Maffei, S / Nappi, R E. ·a Department of Obstetrics and Gynecology , University of Torino School of Medicine, Ospedale Mauriziano Umberto I , Torino , Italy. · b Department of Obstetrics, Gynecology and Pediatrics, Gynecology and Obstetrics Unit , Azienda Policlinico of Modena , Modena , Italy. · c Department of Obstetrics and Gynecology , Pisa University Hospital , Pisa , Italy. · d Department of Woman and Child Health , Policlinico Gemelli Foundation , Rome , Italy. · e Cardiovascular Gynecological Endocrinology Unit, Cardiovascular Endocrinology and Metabolism Department , Italian National Research Council - Regione Toscana "G. Monasterio Foundation" , Pisa , Italy. · f Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S. Matteo Foundation, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences , University of Pavia , Pavia , Italy. ·Climacteric · Pubmed #28453310.

ABSTRACT: Menopausal disorders may include shorter-term symptoms, such as hot flushes and night sweats (vasomotor symptoms, VMS) and longer-term chronic conditions such as cardiovascular disease (CVD), osteoporosis, and cognitive impairment. Initially, no clear link between the shorter-term symptoms and longer-term chronic conditions was evident and these disorders seemed to occur independently from each other. However, there is a growing body of evidence demonstrating that VMS may be a biomarker for chronic disease. In this review, the association between VMS and a range of chronic postmenopausal conditions including CVD, osteoporosis, and cognitive decline is discussed. Prevention of CVD in women, as for men, should be started early, and effective management of chronic disease in postmenopausal women has to start with the awareness that VMS during menopause are harbingers of things to come and should be treated accordingly.

11 Review Vitamin K and osteoporosis: Myth or reality? 2017

Palermo, Andrea / Tuccinardi, Dario / D'Onofrio, Luca / Watanabe, Mikiko / Maggi, Daria / Maurizi, Anna Rita / Greto, Valentina / Buzzetti, Raffaella / Napoli, Nicola / Pozzilli, Paolo / Manfrini, Silvia. ·Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, 00128 Rome, Italy. · Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, 00128 Rome, Italy. Electronic address: d.tuccinardi@unicampus.it. · Department of Experimental Medicine, Polo Pontino, Sapienza University of Rome, 00185 Rome, Italy. · Department of Experimental Medicine, Section of Medical Physiopathology and Endocrinology, Sapienza University of Rome, 00161 Rome, Italy. ·Metabolism · Pubmed #28403946.

ABSTRACT: Vitamin K is a liposoluble vitamin. The predominant dietary form, phylloquinone or vitamin K1, is found in plants and green vegetables; whereas menaquinone, or vitamin K2, is endogenously synthesized by intestinal bacteria and includes several subtypes that differ in side chain length. Aside from its established role in blood clotting, several studies now support a critical function of vitamin K in improving bone health. Vitamin K is in fact required for osteocalcin carboxylation that in turn regulates bone mineral accretion; it seems to promote the transition of osteoblasts to osteocytes and also limits the process of osteoclastogenesis. Several observational and interventional studies have examined the relationship between vitamin K and bone metabolism, but findings are conflicting and unclear. This systematic review aims to investigate the impact of vitamin K (plasma levels, dietary intake, and oral supplementation) on bone health with a particular interest in bone remodeling, mineral density and fragility fractures.

12 Review Non-alcoholic fatty liver disease connections with fat-free tissues: A focus on bone and skeletal muscle. 2017

Poggiogalle, Eleonora / Donini, Lorenzo Maria / Lenzi, Andrea / Chiesa, Claudio / Pacifico, Lucia. ·Eleonora Poggiogalle, Lorenzo Maria Donini, Andrea Lenzi, Department of Experimental Medicine- Medical Pathophysiology, Food Science and Endocrinology Section, Sapienza University of Rome, 00185 Rome, Italy. ·World J Gastroenterol · Pubmed #28348479.

ABSTRACT: The estimates of global incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) are worrisome, due to the parallel burden of obesity and its metabolic complications. Indeed, excess adiposity and insulin resistance represent two of the major risk factors for NAFLD; interestingly, in the last years a growing body of evidence tended to support a novel mechanistic perspective, in which the liver is at the center of a complex interplay involving organs and systems, other than adipose tissue and glucose homeostasis. Bone and the skeletal muscle are fat- free tissues which appeared to be independently associated with NAFLD in several cross-sectional studies. The deterioration of bone mineral density and lean body mass, leading to osteoporosis and sarcopenia, respectively, are age-related processes. The prevalence of NAFLD also increases with age. Beyond physiological aging, the three conditions share some common underlying mechanisms, and their elucidations could be of paramount importance to design more effective treatment strategies for the management of NAFLD. In this review, we provide an overview on epidemiological data as well as on potential contributors to the connections of NAFLD with bone and skeletal muscle.

13 Review Vitamin D and chronic diseases: the current state of the art. 2017

Muscogiuri, Giovanna / Altieri, Barbara / Annweiler, Cedric / Balercia, Giancarlo / Pal, H B / Boucher, Barbara J / Cannell, John J / Foresta, Carlo / Grübler, Martin R / Kotsa, Kalliopi / Mascitelli, Luca / März, Winfried / Orio, Francesco / Pilz, Stefan / Tirabassi, Giacomo / Colao, Annamaria. ·Ios and Coleman Medicina Futura Medical Center, University "Federico II", Naples, Italy. giovanna.muscogiuri@gmail.com. · Department of Endocrinology and Metabolic Diseases, Catholic University of the Sacred Heart, Rome, Italy. · Division of Geriatric Medicine, Department of Neuroscience, Angers University Hospital, University Memory Clinic, UPRES EA 4638, University of Angers, UNAM, Angers, France. · Department of Medical Biophysics, Schulich School of Medicine and Dentistry, Robarts Research Institute, The University of Western Ontario, London, ON, Canada. · Division of Endocrinology, Department of Clinical and Molecular Sciences, Umberto I Hospital, Polytechnic University of Marche, Ancona, Italy. · Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. · The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. · Vitamin D Council, San Luis Obispo, CA, USA. · Department of Medicine, Operative Unit of Andrology and Medicine of Human Reproduction, University of Padova, Padua, Italy. · Department of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria. · Division of Endocrinology and Metabolism, Department of Medicine, AHEPA University Hospital, Thessaloníki, Greece. · Comando Brigata Alpina "Julia"/Multinational Land Force, Medical Service, Udine, Italy. · Medical Clinic V (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany. · Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. · Synlab Academy, Synlab Holding Germany GmbH, Mannheim, Augsburg, Germany. · Department of Endocrinology and Diabetology, Fertility Techniques Structure, University Hospital "S. Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy. · Department of Sports Science and Wellness, "Parthenope" University Naples, Naples, Italy. · Department of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands. · Department of Clinical Medicine and Surgery, University "Federico II", Naples, Italy. ·Arch Toxicol · Pubmed #27425218.

ABSTRACT: The objective was to provide the current state of the art regarding the role of vitamin D in chronic diseases (osteoporosis, cancer, cardiovascular diseases, dementia, autism, type 1 and type 2 diabetes mellitus, male and female fertility). The document was drawn up by panelists that provided their contribution according to their own scientific expertise. Each scientific expert supplied a first draft manuscript on a specific aspect of the document's topic that was subjected to voting by all experts as "yes" (agreement with the content and/or wording) or "no" (disagreement). The adopted rule was that statements supported by ≥75 % of votes would be immediately accepted, while those with <25 % would be rejected outright. Others would be subjected to further discussion and subsequent voting, where ≥67 % support or, in an eventual third round, a majority of ≥50 % would be needed. This document finds that the current evidence support a role for vitamin D in bone health but not in other health conditions. However, subjects with vitamin D deficiency have been found to be at high risk of developing chronic diseases. Therefore, although at the present time there is not sufficient evidence to recommend vitamin D supplementation as treatment of chronic diseases, the treatment of vitamin D deficiency should be desiderable in order to reduce the risk of developing chronic diseases.

14 Review Pregnancy-associated osteoporosis (PAO) with multiple vertebral fragility fractures: diagnosis and treatment in a young primigravid woman. 2016

Pola, E / Colangelo, D / Nasto, L A / Pambianco, V / Autore, G / Formica, V M / Maccauro, G. ·Spinal Unit, Department of Orthopaedics and Traumatology, “A. Gemelli” University Hospital, Catholic University of Rome, Rome, Italy. · Centre for Spine Studies and Surgery, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. · Department of Orthopaedics and Traumatology, “A. Gemelli” University Hospital, Catholic University of Rome, Rome, Italy. ·J Biol Regul Homeost Agents · Pubmed #28002913.

ABSTRACT: PAO is an uncommon condition affecting pregnant women during last trimester or early post-delivery period; it is often asymptomatic or presents with pain related to some acute fragility fractures. The diagnosis is often delayed or missed, the etiology remains unknown and no guidelines about treatment have been published. We present one case of PAO in a 33-year-old primigravid woman presenting acute worsening back pain. Our patient was treated with a TLSO brace, oral 25 (OH)-vitamin D supplementation and Teriparatide for 6 months. A short review of the literature has been included and useful advice about how to suspect and diagnose this uncommon disease were given in order to recognize and treat such a debilitating and severe condition for young mothers as best as possible, based on the available scientific evidences.

15 Review Melatonin as a Potential Agent in the Treatment of Sarcopenia. 2016

Coto-Montes, Ana / Boga, Jose A / Tan, Dun X / Reiter, Russel J. ·Department of Morphology and Cellular Biology, Medicine Faculty, University of Oviedo, Julian Claveria, s/n, Oviedo 33006, Spain. acoto@uniovi.es. · Department of Cellular and Structural Biology, UTHSCSA, San Antonio, TX 78229, USA. acoto@uniovi.es. · Department of Cellular and Structural Biology, UTHSCSA, San Antonio, TX 78229, USA. joseantonio.boga@sespa.es. · Service of Microbiology, Hospital Universitario Central de Asturias, Avenida de Roma, s/n, Oviedo 33011, Spain. joseantonio.boga@sespa.es. · Department of Cellular and Structural Biology, UTHSCSA, San Antonio, TX 78229, USA. tan@uthscsa.edu. · Department of Cellular and Structural Biology, UTHSCSA, San Antonio, TX 78229, USA. reiter@uthscsa.edu. ·Int J Mol Sci · Pubmed #27783055.

ABSTRACT: Considering the increased speed at which the world population is aging, sarcopenia could become an epidemic in this century. This condition currently has no means of prevention or treatment. Melatonin is a highly effective and ubiquitously acting antioxidant and free radical scavenger that is normally produced in all organisms. This molecule has been implicated in a huge number of biological processes, from anticonvulsant properties in children to protective effects on the lung in chronic obstructive pulmonary disease. In this review, we summarize the data which suggest that melatonin may be beneficial in attenuating, reducing or preventing each of the symptoms that characterize sarcopenia. The findings are not limited to sarcopenia, but also apply to osteoporosis-related sarcopenia and to age-related neuromuscular junction dysfunction. Since melatonin has a high safety profile and is drastically reduced in advanced age, its potential utility in the treatment of sarcopenic patients and related dysfunctions should be considered.

16 Review Spinal fractures in patients with ankylosing spondylitis. 2016

Leone, Antonio / Marino, Marzia / Dell'Atti, Claudia / Zecchi, Viola / Magarelli, Nicola / Colosimo, Cesare. ·Institute of Radiology, School of Medicine, Catholic University, Largo A. Gemelli 1, 00168, Rome, Italy. a.leonemd@tiscali.it. · Institute of Radiology, School of Medicine, Catholic University, Largo A. Gemelli 1, 00168, Rome, Italy. ·Rheumatol Int · Pubmed #27379763.

ABSTRACT: The ankylosed spine is prone to fracture even after minor trauma due to its changed biomechanical properties. The two central features of ankylosing spondylitis (AS) that promote the pathological remodeling of the spine are inflammation and new bone formation. AS is also associated with osteoporosis that is attributed to an uncoupling of the bone formation and bone resorption processes. Therefore, bone resorption occurs and promotes weakening of the spine as well as increased risk of vertebral fractures which can be hugely different in terms of clinical relevance. Even in the presence of symptomatic clinical vertebral fractures, the diagnosis can be overruled by attributing the pain to disease activity. Furthermore, given the highly abnormal structure of the spine, vertebral fracture diagnosis can be difficult on the basis of radiography alone. CT can show the fractures in detail. Magnetic resonance imaging is considered the method of choice for the imaging of spinal cord injuries, and a reasonable option for exclusion of occult fractures undetected by CT. Since it is equally important for radiologists and clinicians to have a common knowledge base rather than a compartmentalized view, the aim of this review article was to provide the required clinical knowledge that radiologists need to know and the relevant radiological semiotics that clinicians require in diagnosing clinically significant injury to the ankylosed spine.

17 Review Reverse total shoulder arthroplasty for the management of fractures of the proximal humerus: a systematic review. 2016

Longo, U G / Petrillo, S / Berton, A / Denaro, V. ·Department of Orthopaedic and Trauma Surgery, University Campus Bio-Medico of Rome, Via Álvaro Del Portillo, 200, 00128, Trigoria, RM, Italy. g.longo@unicampus.it. · Department of Orthopaedic and Trauma Surgery, University Campus Bio-Medico of Rome, Via Álvaro Del Portillo, 200, 00128, Trigoria, RM, Italy. ·Musculoskelet Surg · Pubmed #27316439.

ABSTRACT: Reverse total shoulder arthroplasty (RTSA) represents a good solution for the management of patients with fracture of the proximal humerus with associated severe osteoporosis and RC dysfunction. A systematic review of the literature according to the PRISMA guidelines was performed matching the following keywords: "reverse total shoulder arthroplasty"; "reverse total shoulder prostheses"; "fractures"; "fracture of the proximal humerus." Medline, EMBASE, Google Scholar, and Ovid database have been screened. Ten studies were considered in the qualitative analysis. No randomized prospective controlled trials have been found. A total of 256 patients received a RTSA for the management of fracture of the proximal humerus. There were 28 males (10.8 %) and 228 females (89.2 %). The mean age of patients was 75.5 ± 2.2 years (range 70-78 years). The mean follow-up period was 27.8 ± 21.8 months range (6-86 months). Overall, the mean Constant score was 56.7 ± 7.6 points (range 44-67.8 points), the mean DASH score was 39.9 ± 6 points (range 31.5-46.8 points), the ASES averaged 70.3 ± 6.8 points (range 65-78 points), and the OSS averaged 28.7 points (range 15-56 points). RTSA restores function and relieves pain in patients with proximal humeral fractures. However, no randomized controlled trials are available to support RTSA versus osteosintesis, anatomical prostheses or hemiarthroprotesis. Further studies are needed to evaluate the effectiveness of RTSA in the management of fracture of the proximal humerus.

18 Review Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition. 2016

Epstein, S / Defeudis, G / Manfrini, S / Napoli, N / Pozzilli, P / Anonymous5510861. ·Division of Endocrinology, Mount Sinai School of Medicine, New York, NY, USA. · Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy. defeudisg@gmail.com. · Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. defeudisg@gmail.com. · Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy. ·Osteoporos Int · Pubmed #26980458.

ABSTRACT: Diabetes and osteoporosis are rapidly growing diseases. The link between the high fracture incidence in diabetes as compared with the non-diabetic state has recently been recognized. While this review cannot cover every aspect of diabetic osteodystrophy, it attempts to incorporate current information from the First International Symposium on Diabetes and Bone presentations in Rome in 2014. Diabetes and osteoporosis are fast-growing diseases in the western world and are becoming a major problem in the emerging economic nations. Aging of populations worldwide will be responsible for an increased risk in the incidence of osteoporosis and diabetes. Furthermore, the economic burden due to complications of these diseases is enormous and will continue to increase unless public awareness of these diseases, the curbing of obesity, and cost-effective measures are instituted. The link between diabetes and fractures being more common in diabetics than non-diabetics has been widely recognized. At the same time, many questions remain regarding the underlying mechanisms for greater bone fragility in diabetic patients and the best approach to risk assessment and treatment to prevent fractures. Although it cannot cover every aspect of diabetic osteodystrophy, this review will attempt to incorporate current information particularly from the First International Symposium on Diabetes and Bone presentations in Rome in November 2014.

19 Review Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. 2016

Rossini, M / Zanotti, R / Orsolini, G / Tripi, G / Viapiana, O / Idolazzi, L / Zamò, A / Bonadonna, P / Kunnathully, V / Adami, S / Gatti, D. ·Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy. maurizio.rossini@univr.it. · Hematology Section, Department of Medicine, University of Verona, Verona, Italy. · Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy. · Department of Pathology and Diagnostics, University of Verona, Verona, Italy. · Allergy Unit, Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy. ·Osteoporos Int · Pubmed #26892042.

ABSTRACT: Mastocytosis is a rare condition characterized by abnormal mast cell proliferation and a broad spectrum of manifestations, including various organs and tissues. Osteoporosis is one of the most frequent manifestations of systemic mastocytosis, particularly in adults. Osteoporosis secondary to systemic mastocytosis is a cause of unexplained low bone mineral density that should be investigated when accompanied by suspicious clinical elements. Bone involvement is often complicated by a high recurrence of fragility fractures, mainly vertebral, leading to severe disability. The mechanism of bone loss is the result of different pathways, not yet fully discovered. The main actor is the osteoclast with a relative or absolute predominance of bone resorption. Among the stimuli that drive osteoclast activity, the most important one seems to be the RANK-RANKL signaling, but also histamine and other cytokines play a significant role in the process. The central role of osteoclasts made bisphosphonates, as anti-resorptive drugs, the most rational treatment for bone involvement in systemic mastocytosis. There are a few small studies supporting this approach, with large heterogeneity of drug and administration scheme. Currently, zoledronate has the best evidence in terms of gain in bone mineral density and bone turnover suppression, two surrogate markers of anti-fracture efficacy.

20 Review Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. 2016

Hadji, P / Coleman, R E / Wilson, C / Powles, T J / Clézardin, P / Aapro, M / Costa, L / Body, J-J / Markopoulos, C / Santini, D / Diel, I / Di Leo, A / Cameron, D / Dodwell, D / Smith, I / Gnant, M / Gray, R / Harbeck, N / Thurlimann, B / Untch, M / Cortes, J / Martin, M / Albert, U-S / Conte, P-F / Ejlertsen, B / Bergh, J / Kaufmann, M / Holen, I. ·Department of Bone Oncology, Endocrinology and Reproductive Medicine, Philipps-University of Marburg, Frankfurt, Germany. · Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield r.e.coleman@sheffield.ac.uk. · Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield. · Cancer Centre London, Wimbledon, UK. · INSERM, Research Unit UMR403, University of Lyon, School of Medicine Lyon-Est, Lyon, France. · Breast Center of the Multidisciplinary Oncology Institute, Genolier, Switzerland. · Hospital de Santa Maria & Lisbon School of Medicine, Institute of Molecular Biology, Lisbon, Potugal. · CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium. · Medical School, National University of Athens, Athens, Greece. · Medical Oncology, University Campus Bio-medico, Rome, Italy. · Institute for Gynaecological Oncology, Centre for Comprehensive Gynecology, Mannheim, Germany. · Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy. · University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh. · Institute of Oncology, Bexley Wing, St James Hospital Leeds, Leeds. · The Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. · Clinical Trials and Epidemiological Unit, University of Oxford, Oxford, UK. · Breast Center, Department of Obstetrics and Gynaecology, University of Munich, Munich, Germany. · Kantonsspital St Gallen, Breast Center, St Gallen, Switzerland. · Interdisciplinary Breast Cancer Center HELIOS Klinikum Berlin-Buch Germany, Gynecologic Oncology and Obstetrics, Berlin, Germany. · Department of Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona. · Department of Medical Oncology, Institute of Investigation Sanitaria Gregorio Marañón, University Complutense, Madrid, Spain. · Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. · Danish Breast Cancer Cooperative Group Statistical Center Department of Oncology Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. · Karolinska Institute and University Hospital, Stockholm, Sweden. · Institute for Obstetrics and Gynaecology, Goethe University, Frankfurt, Germany. ·Ann Oncol · Pubmed #26681681.

ABSTRACT: Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their ability to prevent cancer treatment-induced bone loss (CTIBL) and reduce the risk of disease recurrence and metastasis. Treatment benefits have been reported but bisphosphonates do not currently have regulatory approval for either of these potential indications. This consensus paper provides a review of the evidence and offers guidance to breast cancer clinicians on the use of bisphosphonates in early breast cancer. Using the nominal group methodology for consensus, a systematic review of the literature was augmented by a workshop held in October 2014 for breast cancer and bone specialists to present and debate the available pre-clinical and clinical evidence for the use of adjuvant bisphosphonates. This was followed by a questionnaire to all members of the writing committee to identify areas of consensus. The panel recommended that bisphosphonates should be considered as part of routine clinical practice for the prevention of CTIBL in all patients with a T score of <-2.0 or ≥2 clinical risk factors for fracture. Compelling evidence from a meta-analysis of trial data of >18,000 patients supports clinically significant benefits of bisphosphonates on the development of bone metastases and breast cancer mortality in post-menopausal women or those receiving ovarian suppression therapy. Therefore, the panel recommends that bisphosphonates (either intravenous zoledronic acid or oral clodronate) are considered as part of the adjuvant breast cancer treatment in this population and the potential benefits and risks discussed with relevant patients.

21 Review The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis. 2015

Pagliari, Danilo / Ciro Tamburrelli, Francesco / Zirio, Gianfranco / Newton, Estelle E / Cianci, Rossella. ·Institute of Internal Medicine, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy. · Institute of Orthopedics, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy. · CytoCure LLC, 100 Cummings Center, Suite 430C, Beverly, MA 01915, USA. ·Anal Cell Pathol (Amst) · Pubmed #26491648.

ABSTRACT: Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue. The etiology and pathogenetic mechanisms of osteoporosis have not been clearly elucidated. Osteoporosis is linked to bone resorption by the activation of the osteoclastogenic process. The breakdown of homeostasis among pro- and antiosteoclastogenic cells causes unbalanced bone remodeling. The complex interactions among these cells in the bone microenvironment involve several mediators and proinflammatory pathways. Thus, we may consider the bone microenvironment as a complex system in which local and systemic immunity are regulated and we propose to consider it as an "immunological niche." The study of the "bone immunological niche" will permit a better understanding of the complex cell trafficking which regulates bone resorption and disease. The goal of a perfect therapy for osteoporosis would be to potentiate good cells and block the bad ones. In this scenario, additional factors may take part in helping or hindering the proosteoblastogenic factors. Several proosteoblastogenic and antiosteoclastogenic agents have already been identified and some have been developed and commercialized as biological therapies for osteoporosis. Targeting the cellular network of the "bone immunological niche" may represent a successful strategy to better understand and treat osteoporosis and its complications.

22 Review [Osteoporosis and major depression: open debate on a bidirectional relationship]. 2015

Carlone, Cristiano / Rusconi, Anna Carlotta / Valeriani, Giuseppe / Todini, Liliana / Coccanari de' Fornari, Maria Antonietta / Biondi, Massimo. ·Dipartimento di Neurologia e Psichiatria, Sapienza Università di Roma. ·Riv Psichiatr · Pubmed #26418596.

ABSTRACT: Osteoporosis and depression are two chronic diseases that affect large population groups with great impact on morbidity, mortality and quality of life. Existing studies of the relationship between depression and osteoporosis have been heterogeneous in their design and use of diagnostic instruments for depression, which might have contributed to the different results on the comorbidity of these two conditions. Moreover, the direction of the causative link is still controversial and the etiology remains unclear. Definitely, limited data suggest that osteoporosis may enhance depressive symptoms, while far more studies have shown that depression adversely affects bone density and increases fracture risk. Thus the correlation of these diseases is still under research. This review comments on a plausible causative relationship and underlying mechanisms that might elucidate the link between two very common diseases. We describe the possible impact of osteoporosis on moods and the effect of depression on bone health. In particular, we focus on the role of the hypothalamic-pituitary-adrenocortical and sympathoadrenal axes, of the parathyroid hormone and cytokines. We also describe the effect of the antidepressant drugs as well as lifestyles that may explain this effect.

23 Review The use of bisphosphonates in women: when to use and when to stop. 2015

Gatti, Davide / Adami, Silvano / Viapiana, Ombretta / Rossini, Maurizio. ·a University of Verona, Rheumatology Unit , Policlinico Borgo Roma Piazzale Scuro 10, Verona, 37134, Italy +39 04 58 12 40 49 ; +39 04 58 12 68 81 ; maurizio.rossini@univr.it. ·Expert Opin Pharmacother · Pubmed #26357942.

ABSTRACT: INTRODUCTION: Bisphosphonates (BPs) are the most commonly used drugs in osteoporosis. AREAS COVERED: This review focuses on the criteria for identifying patients who should be treated with BPs and also the rational for the duration of treatment. EXPERT OPINION: BPs remain the mainstay for the treatment of osteoporosis. For their low cost, the treatment threshold is related exclusively to the ratio between expected benefits and the risk of side effects. This is the case of patients with prior fragility fracture or with low bone density and the presence of other relevant risk factors. The treatment should continue for 3 - 5 years or until fracture risk is no longer high. Afterward a treatment holiday should be considered on the light of the increasing risk of side effects but its duration is still controversial. The duration of this treatment holiday depends on the drug used. Discontinuation of risedronate and ibandronate is associated with the quick loss of the acquired benefits and with these two BPs discontinuation should not exceed 6 months. Alendronate and zoledronate are characterized by a persistent effect after discontinuing treatment and this would allow a more prolonged drug holiday.

24 Review Osteoporosis and cardiovascular disease: an update. 2015

Lello, S / Capozzi, A / Scambia, G. ·a Department of Woman and Child Health , Catholic University , Rome , Italy. ·Gynecol Endocrinol · Pubmed #26036806.

ABSTRACT: Osteoporosis (OP) and cardiovascular diseases (CVD) are the most important causes of mortality and morbility in the elderly. Lots of studies showed a correlation between bone loss and cardiovascular risk mediated by the vascular calcification. The relationship between OP and CVD could be firstly explained by their common risk factors such as age, smoking, alcohol consumption, physical activity and menopause. However, other different hypotheses were proposed to clarify this link. Multiple factors, for example bone morphogenetic proteins, osteoprotegerin, receptor activator of nuclear factor κB ligand, parathyroid hormone, phosphate, oxidized lipids and vitamins D and K seemed to be involved in both conditions, indicating a possible common pathophysiologic mechanism. We review and discuss the available data describing this association. Further studies are necessary to better investigate similarities between OP and CVD.

25 Review Focus on diffusion MR investigations of musculoskeletal tissue to improve osteoporosis diagnosis: a brief practical review. 2015

Capuani, Silvia / Manenti, Guglielmo / Iundusi, Riccardo / Tarantino, Umberto. ·CNR-IPCF UOS Roma Sapienza, Physics Department, "Sapienza" University of Rome, Italy ; Department of Orthopaedics and Traumatology, PTV Foundation, "Tor Vergata" University of Rome, Italy. · Department of Diagnostic and Interventional Radiology, Molecular Imaging and Radiotherapy, PTV Foundation, "Tor Vergata" University of Rome, Italy. · Department of Orthopaedics and Traumatology, PTV Foundation, "Tor Vergata" University of Rome, Italy. ·Biomed Res Int · Pubmed #25861652.

ABSTRACT: Nowadays, a huge number of papers have documented the ability of diffusion magnetic resonance imaging (D-MRI) to highlight normal and pathological conditions in a variety of cerebral, abdominal, and cardiovascular applications. To date, however, the role of D-MRI to investigate musculoskeletal tissue, specifically the cancellous bone, has not been extensively explored. In order to determine potentially useful applications of diffusion techniques in musculoskeletal investigation, D-MRI applications to detect osteoporosis disease were reviewed and further explained.

Next